ORIGINAL RESEARCH article
Front. Immunol., 13 April 2022
Sec. Cancer Immunity and Immunotherapy
Volume 13 - 2022 | https://doi.org/10.3389/fimmu.2022.859331
RETRACTED: CCDC88A Post-Transcriptionally Regulates VEGF via miR-101 and Subsequently Regulates Hepatocellular Carcinoma
- QH
Qiongying Hu 1
- YL
Yuchen Li 1
- HC
Hongqing Chen 1
- HL
Hongyan Liao 2
- YH
Yong He 2
- QZ
Qin Zheng 2*
1. Department of Laboratory Medicine, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, China
2. Department of Laboratory Medicine, West China Hospital of Sichuan University, Chengdu, China
Summary
Citation
Hu Q, Li Y, Chen H, Liao H, He Y and Zheng Q (2022) RETRACTED: CCDC88A Post-Transcriptionally Regulates VEGF via miR-101 and Subsequently Regulates Hepatocellular Carcinoma. Front. Immunol. 13:859331. doi: 10.3389/fimmu.2022.859331
Received
04 February 2022
Accepted
14 March 2022
Published
13 April 2022
Volume
13 - 2022
Edited by
Saravanan Sekaran, Saveetha Dental College and Hospitals, India
Reviewed by
Ananth Kumar Kammala, University of Texas Medical Branch at Galveston, United States; Ezhilarasan Devaraj, Saveetha University, India
Updates
This article was submitted to Cancer Immunity and Immunotherapy, a section of the journal Frontiers in Immunology
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.